Diacylglycerol acyl transferase 2 inhibitors

Inventors: Markus Boehm (Mansfield, MA); Shawn Cabral (Groton, CT); Matthew S. Dowling (Old Lyme, CT); Kentaro Futatsugi (Qunicy, MA); Kim Huard (Berkeley, CA); Esther Cheng Yin Lee (Newton, MA); Allyn T. Londregan (Barrington, RI); Jana Polivkova (Mystic, CT); David A. Price (Concord, MA); Qifang Li (Stonington, CT)

Assignee: Pfizer Inc.

C07D405/14 A61K31/506 A61K45/06 C07D401/14 C07D409/14 A61P3/00 A61P3/06 A61P3/10 C07B2200/13

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12703696
App. No.: 18/520,638
Granted: Aug 11, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Claims (26)

1 . A method for reduction of triglyceride level in a human, wherein the method comprises a step of administering to the human in need of such reduction an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt of said compound, wherein the compound of Formula (I) is:

wherein

D 1 and D 2 are each independently N or CH;

R 1 is H, or (C 1 -C 2 )alkyl optionally substituted with one or two substituents each independently selected from fluoro and (C 3 -C 6 ) cycloalkyl;

R 2 is H or fluoro;

R 3 is

R 4 is H, cyano, or (C 1 -C 4 )alkyl optionally substituted with one or two substituents each independently selected from —OH and —S(O) 2 R 6 ;

R 5 is H or —OH; and

R 6 is (C 1 -C 4 )alkyl.

2 . The method of claim 1 wherein the method reduces triglyceride level in plasma, liver, or a combination thereof of the human.

3 . The method of claim 2 wherein the method reduces triglyceride level in liver of the human.

4 . The method of claim 1 wherein the compound of Formula (I) is

or a pharmaceutically acceptable salt thereof.

5 . The method of claim 2 wherein the compound of Formula (I) is

or a pharmaceutically acceptable salt thereof.

6 . The method of claim 3 wherein the compound of Formula (I) is

or a pharmaceutically acceptable salt thereof.

7 . The method of claim 1 wherein the compound of Formula (I) is

8 . The method of claim 2 wherein the compound of Formula (I) is

9 . The method of claim 3 wherein the compound of Formula (I) is

10 . The method of claim 1 wherein the compound of Formula (I) is 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof.

11 . The method of claim 2 wherein the compound of Formula (I) is 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof.

12 . The method of claim 3 wherein the compound of Formula (I) is 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof.

13 . The method of claim 1 wherein the compound of Formula (I) is 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide.

14 . The method of claim 2 wherein the compound of Formula (I) is 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide.

15 . The method of claim 3 wherein the compound of Formula (I) is 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide.